Document Detail

Encouraging preliminary results in 12 patients with high-risk haematological malignancies by omitting graft-versus-host disease prophylaxis after allogeneic transplantation.
MedLine Citation:
PMID:  11122119     Owner:  NLM     Status:  MEDLINE    
Immunosuppressive therapy, routinely given after allogeneic transplantation to modulate graft-versus-host disease (GVHD) may have an adverse effect on the graft-versus-tumour (GVT) effect. Twelve patients with high-risk haematological malignancies were given cyclophosphamide, total body irradiation and antithymocyte globulin followed by peripheral blood stem cell grafts from HLA-identical siblings without prophylactic immunosuppression. At the earliest clinical evidence of GVHD, patients were treated with high-dose solumedrol and tacrolimus. Prompt haematological recovery [absolute neutrophil count (ANC) > 1.0 x 109/l] was observed (median time 9 d). All patients developed grade III-IV GVHD (median onset 9 d), involving the skin (11), intestine (five) and liver (three). Of nine evaluable patients, seven developed chronic GVHD [extensive (six), limited (one)]. Six patients died 1-6.5 months after transplantation. Three patients died from treatment-related complications, two from acute GVHD and one from relapsing disease. The remaining six patients are alive 5-26 months after transplantation, five in complete remission and one myeloma patient in very good partial remission. In conclusion, omission of post-transplantation GVHD prophylaxis is feasible, does not lead to graft failure or a high incidence of uncontrollable GVHD and appears to be associated with encouraging clinical responses in a group of patients with high-risk disease features.
A B Fassas; A P Rapoport; M Cottler-Fox; T Chen; G Tricot
Related Documents :
15620459 - Severe, late-onset graft-versus-host disease in a liver transplant recipient documented...
18679369 - Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: a journey of...
3519429 - Epithelial denudement in the gastrointestinal tracts of two bone marrow transplant reci...
15361909 - Regimen-related toxicity following reduced-intensity stem-cell transplantation (rist): ...
10163549 - Peripheral blood stem cell collection from healthy donors for allogeneic transplantation.
18503989 - Modulating graft-versus-host disease to enhance the graft-versus-leukemia effect.
8329409 - Immunoglobulin m antibodies in transplanted human hearts.
18347569 - Prognostic value of serum surfactant protein d level prior to transplant for the develo...
15125039 - Morphology, development and comparative anatomical evaluation of the testicular excreto...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  British journal of haematology     Volume:  111     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2000 Nov 
Date Detail:
Created Date:  2001-01-08     Completed Date:  2001-02-15     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  662-7     Citation Subset:  IM    
Bone Marrow Transplant Program, Department of Internal Medicine, University of Maryland, Baltimore, MD, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Bone Marrow Transplantation*
Follow-Up Studies
Glucocorticoids / therapeutic use
Graft vs Host Disease / drug therapy
Graft vs Tumor Effect*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology,  surgery*
Leukemia, Myeloid / immunology,  surgery*
Leukemia-Lymphoma, Adult T-Cell / immunology,  surgery
Lymphoma, B-Cell / immunology,  surgery*
Lymphoma, Mantle-Cell / immunology,  surgery
Middle Aged
Multiple Myeloma / immunology,  surgery
Pilot Projects
Prednisone / therapeutic use
Transplantation, Homologous
Reg. No./Substance:
0/Glucocorticoids; 53-03-2/Prednisone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Parvovirus B19 transmitted by bone marrow.
Next Document:  OKT-3-based reconditioning regimen for early graft failure in HLA-non-identical stem cell transplant...